logo
episode-header-image
Jun 2023
36m 43s

Talk Evidence - post pandemic pruning, b...

The BMJ
About this episode

In this episode of Talk Evidence,  Helen Macdonald, Joe Ross, and Juan Franco are back to update us on what's happening in the world of medical evidence.

Firstly, the news about the end of the covid-19 pandemic was trumpeted, but the changes to research funding have been more quite - and the team discuss what this means for ongoing work to understand the effects of covid, but also in terms of preparedness for the next pandemic.

Next, breast cancer screening recommendations, in the USA, have been reduced from women over the age of 50, to those over the age of 40. We discuss the modelling study which lead to that recommendation change, and what the consequence may be in terms of overdiagnosis.

Finally, 40 years ago, the U.S. Orphan Drug act was passed to encourage the development of treatments for rare conditions - but new research looks at how many clinically useful drugs have come onto market, and an analysis examines the way in which the system could be gamed by narrowing disease definitions to create small populations of patients.

 

Reading list

Is the UK losing its world leading covid surveillance network just when it needs it most?

Breast cancer: US recommends women start screening at 40

FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications

 

 

Up next
Jul 1
Time to rethink GP's advice on weightloss, and ticagrelor data doubts
Last December, The BMJ published an investigation into the 2009 PLATO trial - exposing serious problems with that study’s data analysis and reporting. Our follow up investigation has shown that those data problems extend to other key supporting evidence in AstraZeneca’s initial a ... Show More
33m 38s
Jun 16
The plan for NHS league tables is bad, and will lead to unintended consequences
In this episode, we hear about ketamine addiction. It's in the news, but the rise in addiction amongst young people in the UK has caused concern for some time. Irene Guerrini and Nicola Kalk, both addiction psychiatrists from the National Addiction Centre, join us to explain why ... Show More
26m 9s
Jun 2
Wellness industry lies, and preventative AI evaluation
Devi Sridhar's new book “How Not to Die (Too Soon) - The Lies We’ve Been Sold, and the Policies That Could Save Us” is focussing on the way wellness culture ignores the societal context in which health is really created. As a trained personal trainer and professor of global publi ... Show More
38m 53s
Recommended Episodes
Apr 2024
Are more young people getting cancer?
Last month, Catherine, Princess of Wales shared she’d been diagnosed with cancer. Describing this news as ‘a huge shock’ and at age just 42, the Princess’ disease falls into a category known as “early-onset cancer” – when the disease affects those under 50. While cases in this ag ... Show More
27m 39s
Jun 2022
Talk Evidence - political persuasion and mortality, too much medicine
In this week's episode, Helen Macdonald is joined by Joseph Ross, US research editor for The BMJ, and Juan Franco, editor of BMJ EBM. They begin by discussing a review of obesity interventions in primary care, and Joe wonders if GPs are really the best people to tackle the issue. ... Show More
41m 6s
Nov 2023
#278 ‒ Breast cancer: how to catch, treat, and survive breast cancer | Harold Burstein, M.D., Ph.D.
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Harold (Hal) Burstein is an internationally renowned breast cancer expert. In this episode, Hal discusses a broad range of topics related to breast ... Show More
2h 10m
Oct 2023
The controversy over lowering the age of breast cancer screening
In Canada, 1 in 8 women will be diagnosed with breast cancer in their lifetime. It’s the second leading cause of death from cancer in Canadian women and second most common cancer in the country. Currently, guidelines say that screening should begin at the age of 50, but the task ... Show More
19m 11s
Aug 2022
Chemotherapy and Targeted Therapy for HER2-Negative Metastatic Breast Cancer that is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update
An interview with Dr. Beverly Moy from Massachusetts General Hospital in Boston, MA, lead author on "Chemotherapy and Targeted Therapy for HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation ... Show More
8m 47s
Aug 2019
Lungenkrebs und das Lungenkrebsscreening: neue diagnostische und therapeutische Methoden
Die Diagnostik des Lungenkrebses ist ausgesprochen wichtig, da die Behandlungsmethoden trotz einer Reihe wesentlichen Innovationen immer noch dazu führen, dass Lungenkrebs eine der häufigsten Todesursachen an Krebserkrankungen darstellt. Um eine frühe Erkennung zu gewährleisten, ... Show More
3m 44s
Aug 2023
#267 ‒ The latest in cancer therapeutics, diagnostics, and early detection | Keith Flaherty, M.D.
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Keith Flaherty is the director of clinical research at the Massachusetts General Hospital Cancer Center and a previous guest on The Drive. In this e ... Show More
1h 50m
Aug 2023
How Oncologists Are Confronting the Cancer Drug Shortage
Drs. Vamsi Velcheti, Taofeek Owonikoko, and Janakiraman Subramanian discuss their experiences navigating the cancer drug shortage in the United States, the impact on patients and clinical trial enrollment, lessons learned, and proactive strategies to mitigate future crises. TRANS ... Show More
25m 17s
May 2024
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer – CDK4/6 Inhibitors Rapid Update
Dr. Rachel Freedman and Dr. Sharon Giordano share the latest rapid guideline update from ASCO on the adjuvant use of the CDK4/6 inhibitors abemaciclib and ribociclib in patients with stage II and III breast cancer. They share details on the impetus for the update, supporting evid ... Show More
11m 23s
Jan 2023
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer Rapid Recommendation Update
Dr. Beverly Moy is back on the ASCO Guidelines Podcast to discuss the latest guideline rapid recommendation update regarding sacituzumab govitecan for patients with hormone receptor-positive HER2-negative metastatic breast cancer based on recent evidence published in TROPiCS-02. ... Show More
7m 7s